NCT05155007View on ClinicalTrials.gov

A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

February 4, 2022

Study Completion Date

February 4, 2022

Conditions

Healthy

Interventions

DRUG

Rilematovir

Rilematovir will be administered orally as per assigned treatment sequence.

DRUG

Ciclosporin

Ciclosporin will be administered orally as per assigned treatment sequence.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT05155007 - A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir | Biotech Hunter | Biotech Hunter